India, May 5 -- Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program following a data-driven review. Shares are down nearly 5% in pre-market trading.
The clinical programs that are being deprioritized are REC-2282, REC-994, and REC-3964.
The company is discontinuing the development of REC-2282, which was being investigated for NF2-driven meningioma and neurofibromatosis type 2, as well as REC-994, which was aimed at treating symptomatic cerebral cavernous malformations, as the overall data no longer support continuing either program.
For REC-3964, which is under phase II trial for preventing recurrent C. difficil...